Avalo Therapeutics, Inc. (CERC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1152038,
    "name": "Avalo Therapeutics, Inc.",
    "stock_name": "Avalo Therapeutics, Inc.",
    "full_name": "Avalo Therapeutics, Inc.",
    "name_url": "stocks-analysis/avalo-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "17.95",
    "chg": 2.08,
    "chgp": "13.11%",
    "dir": 1,
    "prev_price": "15.87",
    "mcapval": "150.07",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US05338F3064",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "762.17 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/avalo-therapeutics-inc-1152038-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Avalo Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-avalo-therapeutics-inc-technically-bullish-or-bearish-3547302",
        "imagepath": "",
        "date": "2025-09-20 19:52:12",
        "description": "As of 3 September 2025, the technical trend for Avalo Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The monthly MACD and KST are mildly bullish, indicating some strength in the longer term. \n\nIn terms of performance, Avalo has outperformed the S&P 500 significantly over the past week (9.19% vs. 1.05%) and month (31.13% vs. 2.33%), while the year-to-date return of 59.89% also surpasses the S&P's 12.22%. However, the longer-term returns over 3 years and 5 years show substantial declines compared to the S&P 500. Overall, the current technical indicators suggest a strong bullish sentiment in the short to medium term...."
      },
      {
        "title": "Is Avalo Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-avalo-therapeutics-inc-overvalued-or-undervalued-3543703",
        "imagepath": "",
        "date": "2025-09-20 18:26:25",
        "description": "As of 8 July 2024, Avalo Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. Given the current metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 0.36, an EV to EBIT of 1.55, and an EV to EBITDA of 1.56, which suggest that the company is not generating sufficient value relative to its market price.\n\nIn comparison to peers, Avalo's valuation ratios are significantly lower, with 180 Life Sciences Corp. showing an EV to EBITDA of -61.84 and ABVC BioPharma, Inc. at -23.18, indicating that Avalo is not alone in facing valuation challenges within its sector. Despite recent stock performance showing a 59.89% year-to-date return compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a staggering -99.85% return over the past five years...."
      }
    ],
    "total": 7,
    "sid": "1152038",
    "stock_news_url": "https://www.marketsmojo.com/news/avalo-therapeutics-inc-1152038"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Avalo Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:52:12

As of 3 September 2025, the technical trend for Avalo Therapeutics, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The weekly MACD, Bollinger Bands, and OBV are all bullish, while the daily moving averages also confirm a bullish trend. The monthly MACD and KST are mildly bullish, indicating some strength in the longer term. In terms of performance, Avalo has outperformed the S&P 500 significantly over the past week (9.19% vs. 1.05%) and month (31.13% vs. 2.33%), while the year-to-date return of 59.89% also surpasses the S&P's 12.22%. However, the longer-term returns over 3 years and 5 years show substantial declines compared to the S&P 500. Overall, the current technical indicators suggest a strong bullish sentiment in the short to medium term....

Is Avalo Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:26:25

As of 8 July 2024, Avalo Therapeutics, Inc. has moved from a risky valuation grade to one that does not qualify. Given the current metrics, the company appears to be overvalued. Key ratios include a Price to Book Value of 0.36, an EV to EBIT of 1.55, and an EV to EBITDA of 1.56, which suggest that the company is not generating sufficient value relative to its market price. In comparison to peers, Avalo's valuation ratios are significantly lower, with 180 Life Sciences Corp. showing an EV to EBITDA of -61.84 and ABVC BioPharma, Inc. at -23.18, indicating that Avalo is not alone in facing valuation challenges within its sector. Despite recent stock performance showing a 59.89% year-to-date return compared to the S&P 500's 12.22%, the long-term outlook remains concerning, particularly with a staggering -99.85% return over the past five years....

View All News